Loading...
•
Jun 30, 2024
Aytu BioScience Q4 2024 Earnings Report
Aytu BioScience reported Q4 2024 earnings with a focus on Rx Segment growth and the completed wind-down of the Consumer Health Segment.
Key Takeaways
Aytu BioScience reported Q4 2024 consolidated net revenue of $18.0 million compared to $30.7 million in the prior year period. The company's net loss was $4.6 million, or $0.82 net loss per share, compared to a net loss of $2.5 million, or $0.59 net loss per share, in Q4 2023. Consolidated adjusted EBITDA was $1.5 million in Q4 2024, compared to $7.7 million in Q4 2023.
Consolidated net revenue was $18.0 million, reflecting the wind down of the Consumer Health Segment and changes in payor coverage impacting the Pediatric Portfolio.
ADHD Portfolio net revenue decreased 13% to $13.8 million, attributed to timing differences.
Rx Segment gross margin improved to 76% compared to 75% in Q4 2023.
The company completed the wind down and divestiture of its Consumer Health Segment in July 2024.
Revenue by Segment
Forward Guidance
The Company expects Rx Segment net revenue and adjusted EBITDA growth in fiscal 2025 from current levels.
Positive Outlook
- Rx Segment net revenue growth expected in fiscal 2025.
- Adjusted EBITDA growth expected in fiscal 2025.
- Focus on driving prescription growth and leveraging the Aytu RxConnect program.
- Confidence in Pediatric Portfolio returning to growth with implemented commercial initiatives.
- Strategic focus on cash flows and earnings to enhance the financial profile.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...